Marksans Pharma unit gets UK marketing nod for key products

Marksans Pharma Limited announced on October 15, 2025, that its wholly-owned UK subsidiary, Relonchem Limited, has received marketing authorization from the UK MHRA for two products: Clonidine 100 microgram Tablets and Clonidine Hydrochloride 25 microgram Tablets. This authorization signifies a significant regulatory milestone for the company's expansion in the UK market.

Marksans Pharma, headquartered in Mumbai, India, specializes in the research, manufacturing, and marketing of generic pharmaceutical formulations globally. Its manufacturing facilities in India, USA, and UK are approved by leading regulatory agencies including the USFDA, UKMHRA, and Australian TGA.

The company boasts a diverse product portfolio across major therapeutic segments such as CVS, CNS, anti-diabetic, pain management, gastroenterological, and anti-allergies, which it markets worldwide. The new marketing authorizations are expected to enhance its global product reach.